April 10, 2018 / 5:07 PM / 5 months ago

BRIEF-Five Prime Therapeutics To Close Bladder Cancer Cohort Of Its Phase 1 FPA144-001 Trial

April 10 (Reuters) - Five Prime Therapeutics Inc:

* TO CLOSE BLADDER CANCER COHORT OF PHASE 1 TRIAL EVALUATING BEMARITUZUMAB TREATING PATIENTS WHOSE TUMORS OVEREXPRESS FGFR2B PROTEIN

* SAYS TO CONTINUE TREATING BLADDER CANCER PATIENTS CURRENTLY ON STUDY BUT WILL NOT ENROLL ADDITIONAL PATIENTS IN COHORT-SEC FILING Source text: (bit.ly/2HnAIag) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below